SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2004 / Cilt: 10 - Sayı: 2

Adding metformin to the oral contraceptive treatment for hirsutism has no additional effect on Ferriman-Gallwey scores in hirsute women with PCOS: A randomized controlled study

Koray ELTER
Gonca İMİR
Emine AY
Fatih DURMUŞOĞLU
Pages
101–105
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSIONS: Adding metformin to the OCP treatment may result in additional benefits, but does not improve hirsutism over the OCP treatment alone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To analyze the additional benefits of adding metformin to the oral contraceptive pill (OCP) treatment in lean women with PCOS.
📊
Key Findings & Data:STUDY DESIGN: After a baseline work-up including BMI, waist-to-hip ratio, Ferriman-Gallwey (FG) score, serum hormone, SHBG, fasting glucose and insulin levels, 28 nonobese women with PCOS were randomized either to the OCP or to the OCP-plus-metformin treatment.
💡
Conclusion & Impact:CONCLUSIONS: Adding metformin to the OCP treatment may result in additional benefits, but does not improve hirsutism over the OCP treatment alone.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Siproteron asetat · Polikistik yumurtalık sendromu · Hirsutizm

Abstract

OBJECTIVE: To analyze the additional benefits of adding metformin to the oral contraceptive pill (OCP) treatment in lean women with PCOS. STUDY DESIGN: After a baseline work-up including BMI, waist-to-hip ratio, Ferriman-Gallwey (FG) score, serum hormone, SHBG, fasting glucose and insulin levels, 28 nonobese women with PCOS were randomized either to the OCP or to the OCP-plus-metformin treatment. At the end of the 4-month follow-up period, subjects were re-evaluated. RESULTS: The two groups were similar at baseline. The effects of the two treatments on the FG score were similar. Subjects, who received OCP-plus-metformin had significantly higher reductions in serum androstenedione than those, who received OCP alone. Fasting glucose-to-insulin ratio improved significantly in the OCP-plus-metformin group, while OCP treatment alone did not cause any significant change. CONCLUSIONS: Adding metformin to the OCP treatment may result in additional benefits, but does not improve hirsutism over the OCP treatment alone.

🔖

Cite This Article

ELTER, K., İMİR, G., AY, E., DURMUŞOĞLU, F. (2004). Adding metformin to the oral contraceptive treatment for hirsutism has no additional effect on Ferriman-Gallwey scores in hirsute women with PCOS: A randomized controlled study. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 10 - Sayı: 2, 101–105. https://ajindex.com/articles/227167

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440-7
  2. Barth JH, Catalan J, Cherry CA, Day A. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res 1993; 37:615-9
  3. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21:347-62
  4. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815-30
  5. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82:4075-9
  6. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81:2854-64
  7. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986; 45:327-33
  8. Zacur HA. Polycystic ovary syndrome, hyperandrogenism, and insulin resistance. Obstet Gynecol Clin North Am 2001; 28:21-33
  9. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001; 76:517-24
  10. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003; 79:1-13
  11. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73:1149-54
  12. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767-74
  13. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998; 69:691-6
  14. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in